The AG1478 tyrosine kinase inhibitor is an effective suppressor of leiomyoma cell growth

Human Reproduction

Volumn 19, Issue 9, 2004, Pages 1957-1967

  Shushan, Asher ^a   Rojansky, Nathan ^a   Laufer, Neri ^a   Klein, Benjamin Y ^a   Shlomai, Zipora ^a   Levitzki, Rubina ^a   Hartzstark, Zipora ^a   Ben Bassat, Hannah ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

AG1478; Growth suppression; Leiomyomas; Protein tyrosine kinase (PTK) inhibitors; Signal transduction therapy

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRADIOL; ESTROGEN; PHOSPHOTYROSINE; PROGESTERONE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN TYROSINE KINASE INHIBITOR; STEROID HORMONE;

ADULT; APOPTOSIS; ARTICLE; CELL CYCLE; CELL GROWTH; CELL ISOLATION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONSERVATIVE TREATMENT; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; DRUG TARGETING; DRUG WITHDRAWAL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GROWTH INHIBITION; GROWTH REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCHEMISTRY; INHIBITION KINETICS; MYOMETRIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE CULTURE; TREATMENT OUTCOME; UTERUS MYOMA; WESTERN BLOTTING;

EID: 4544313842     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/deh355     Document Type: Article

References (42)

1. Anania CA, Stewart EA, Quade BJ, Hill JA and Nowak RA (1997) Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod 3,685-691.
2. Ben-Bassat H and Klein BY (2000) Inhibitors of tyrosine kinases in the treatment of psoriasis. Curr Pharm Des 6,933-942.
3. Ben-Bassat H, Rosenbaum-Mitrani S, Hartzstark Z, Shlomai Z, Kleinberger-Doron N, Gazit A, Plowman G, Levitzki R, Tsvieli R and Levitzki A (1997) Inhibitors of epidermal growth factor receptor kinase and of cyclin-dependent kinase 2 activation induce growth arrest, differentiation, and apoptosis of human papilloma virus 16-immortalized human keratinocytes. Cancer Res 57,3741-3750.
4. Buttram VC Jr and Reiter RC (1981) Uterine leiomyomata: etiology, symptomatology, and management. Fertil Steril 36,433-445.
5. Chegini N, Ma C, Tang XM and Williams RS (2002) Effects of GnRH analogues, 'add-back' steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 8,1071-1078.
6. Dixon D, Flake GP, Moore AB, He H, Haseman JK, Risinger JI, Lancaster JM, Berchuck A, Barrett JC and Robboy SJ (2002) Cell proliferation and apoptosis in human uterine leiomyomas and myometria. Virchows Arch 441,53-62.
7. Fedele L, Parazzini F, Luchini L, Mezzopane R, Tozzi L and Villa L (1995) Recurrence of fibroids after myomectomy: a transvaginal ultrasonographic study. Hum Reprod 10,1795-1796.
8. Flake GP, Andersen J and Dixon D (2003) Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111,1037-1054.
9. Friedman AJ, Daly M, Juneau-Norcross M, Rein MS, Fine C, Gleason R and Leboff M (1993) A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin 'add-back' regimens for women with leiomyomata uteri. J Clin Endocrinol Metab 76, 1439-1445.
10. Friedman AJ, Daly M, Juneau-Norcross M, Gleason R, Rein MS and LeBoff M (1994) Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin 'add-back' for 2 years. Hum Reprod 9,1618-1625.
11. Gao Z, Matsuo H, Wang Y, Nakago S and Maruo T (2001) Up-regulation by IGF-I of proliferating cell nuclear antigen and Bcl-2 protein expression in human uterine leiomyoma cells. J Clin Endocrinol Metab 86,5593-5599.
12. Gao Z, Matsuo H, Nakago S, Kurachi O and Maruo T (2002) p53 tumor suppressor protein content in human uterine leiomyomas and its down-regulation by 17 beta-estradiol. J Clin Endocrinol Metab 87,3915-3920.
13. Gazit A, Chen J, App H, McMahon G, Hirth P, Chen I and Levitzkj A (1996) Tyrphostins IV - highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines. Bioorg Med Chem 4,1203-1207.
14. Guarnaccia MM and Rein MS (2001) Traditional surgical approaches to uterine fibroids: abdominal myomectomy and hysterectomy. Clin Obstet Gynecol 44,385-400.
15. Hofmann GE, Rao CV, Barrows GH, Schultz GS and Sanfilippo JS (1984) Binding sites for epidermal growth factor in human uterine tissues and leiomyomas. J Clin Endocrinol Metab 58,880-884.
16. Huet-Hudson YM, Chakraborty C, De SK, Suzuki Y, Andrews GK and Dey SK (1990) Estrogen regulates the synthesis of epidermal growth factor in mouse uterine epithelial cells. Mol Endocrinol 4,510-523.
17. Lee BS, Stewart EA, Sahakian M and Nowak RA (1998) Interferon-alpha is a potent inhibitor of basic fibroblast growth factor-stimulated cell proliferation in human uterine cells. Am J Reprod Immunol 40,19-25.
18. Lefebvre G, Vilos G, Allaire C, Jeffrey J, Arneja J, Birch C, Fortier M and Wagner M (2003) The management of uterine leiomyomas. J Obstet Gynaecol Can 25,396-418, quiz 419-322.
19. Lethaby A, Vollenhoven B and Sowter M (2002) Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. Br J Obstet Gynaecol 109,1097-1108.
20. Levitzki A (1992) Tyrphostins: tyrosine kinase blockers as novel antiproliferative agents and dissectors of signal transduction. FASEB J 6, 3275-3282.
21. Levitzki A (1999) Protein tyrosine kinase inhibitors as novel therapeutic agents. Pharmacol Ther 82,231-239.
22. Levitzki A (2001) The selectivity of small molecules towards protein tyrosine kinases. Ernst Schering Research Foundatio Workshop,71-80.
23. Levitzki A and Gazit A (1995) Tyrosine kinase inhibition: an approach to drug development. Science 267,1782-1788.
24. Liu CH, Lin YS, Lin CC, Tzeng CC and Chou CY (1993) Medical treatment of uterine myoma with long-acting gonadotropin-releasing hormone agonist prior to myomectomy. J Formosan Med Assoc 92,536-539.
25. Maruo T, Matsuo H, Samoto T, Shimomura Y, Kurachi O, Gao Z, Wang Y, Spitz IM and Johansson E (2000) Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 65,585-592.
26. Matsuo H, Maruo T and Samoto T (1997) Increased expression of Bcl-2 protein in human uterine leiomyoma and its up-regulation by progesterone. J Clin Endocrinol Metab 82,293-299.
27. Matsuo H, Kurachi O, Shimomura Y, Samoto T and Maruo T (1999) Molecular bases for the actions of ovarian sex steroids in the regulation of proliferation and apoptosis of human uterine leiomyoma. Oncology 57,49-58.
28. Minakuchi K, Kawamura N, Tsujimura A and Ogita S (1999) Remarkable and persistent shrinkage of uterine leiomyoma associated with interferon alfa treatment for hepatitis. Lancet 353,2127-2128.
29. Myers ER, Barber MD, Gustilo-Ashby T, Couchman G, Matchar DB and McCrory DC (2002) Management of uterine leiomyomata: what do we really know? Obstet Gynecol 100,8-17.
30. Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, Cavenee WK and Huang HJ (2001) Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg 95,472-479.
31. Nowak RA (2001) Identification of new therapies for leiomyomas: what in vitro studies can tell us. Clin Obstet Gynecol 44,327-334.
32. Powell TJ, Ben-Bassat H, Klein BY, Chen H, Shenoy N, McCullough J, Narog B, Gazit A, Harzstark Z, Chaouat M, Levitzki R, Tang C, McMahon J, Shawver L and Levitzki A (1999) Growth inhibition of psoriatic keratinocytes by quinazoline tyrosine kinase inhibitors. Br J Dermatol 141,802-810.
33. Rein MS (2000) Advances in uterine leiomyoma research: the progesterone hypothesis. Environ Health Perspect 108,791-793.
34. Rein MS, Barbieri RL and Friedman AJ (1995) Progesterone: a critical role in the pathogenesis of uterine myomas. Am J Obstet Gynecol 172,14-18.
35. Severino MF, Murray MJ, Brandon DD, Clinton GM, Burry KA and Novy MJ (1996) Rapid loss of oestrogen and progesterone receptors in human leiomyoma and myometrial explant cultures. Mol Hum Reprod 2, 823-828.
36. Shimomura Y, Matsuo H, Samoto T and Maruo T (1998) Up-regulation by progesterone of proliferating cell nuclear antigen and epidermal growth factor expression in human uterine leiomyoma. J Clin Endocrinol Metab 83,2192-2198.
37. Sozen I and Arici A (2002) Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 78,1-12.
38. Steinbach JP, Supra P, Huang HJ, Cavenee WK and Weller M (2002) CD95-mediated apoptosis of human glioma cells: modulation by epidermal growth factor receptor activity. Brain Pathol 12,12-20.
39. Stewart E (2001a) Uterine fibroids. Lancet 357,293-298.
40. Stewart E (2001b) Gonadotropins and the uterus: is there a gonad-independent pathway? J Soc Gynecol Invest 8,319-326.
41. Stewart EA, Gedroyc WMW, Tempany CMC, Quade BJ, Inbar Y, Ehrenstein T, Shushan A, Hindley JT, Goldin RD, David M et al. (2003) Focused ultrasound treatment of uterine fibroid tumors: safety and feasibility of a noninvasive thermoablative technique. Am J Obstet Gynecol 189,48-54.
42. Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z and Peterson HB (1994) Hysterectomy in the United States, 1988-1990. Obstet Gynecol 83,549-555.